Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Ind-Swift Labs Gets US FDA Nod For 5 APIs For Its Derabassi Facility

Pharma major Ind-Swift Laboratories Ltd. has obtained the US FDA nod for its five Active Pharmaceutical Ingredients or APIs manufactured at its Derabassi manufacturing facility.

The products for which the company has obtained the approval are Naratriptan Hydrochloride (anti-migraine), Ropinirole Hydrochloride (anti-Parkinson's disease), Donepezil Hydrochloride (anti-Alzheimer's disease), Acamprosate Calcium (anti-alcohol dependence) and Clarithromycin (Macrolide antibiotic).

With this approval, the company will be able to sell its products in the US market. The worldwide market for these products is $5 billion.

The company's Derabassi facility is already accredited by key accreditation agencies such as TGA, MHRA, COS, KFDA and PMDA.

Commenting on the development, Vice Chairman and Managing Director N.R. Munjal said, "This multi product approval will give multifold aggression to the sales as we have good presence in US through our US subsidiary and we expect this approval to give additional 50 percent to 60 percent growth in US sales."

At the BSE, Ind-Swift Laboratories closed Tuesday's trading at Rs.98.65, up 3.30 percent from the previous close.

Click here to receive FREE breaking news email alerts for Ind-Swift Laboratories Ltd. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Looking to increase pressure on Congress, the White House released a report on Tuesday warning of the economic costs of delaying action to address climate change. With the August recess looming, House Republican leaders are hopeful they can pass legislation to address the crisis along the U.S.-Mexico border before the end of the week. The House is expected to vote on a bill providing $659 million in funding for the border crisis, well below the $3.7 billion requested by the Obama administration. After moving mostly higher in early trading on Tuesday, stocks have given back ground over the course of the trading session. A negative reaction to news of new European sanctions against Russia contributed to the pullback by the markets.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.